Την Δευτέρα 7 Ιουνίου, ώρα 5 μμ, θα πραγματοποιηθεί τηλεδιάλεξη με προσκεκλημένο ομιλητή τον Dr. Andrea Carfi, Vice-President of Moderna & Head of Research for Infectious Disease.
ΘΕΜΑ: “Development of Moderna COVID-19 vaccine and preparing for variants of concern”
Η τηλεδιάλεξη πραγματοποιείται στο πλαίσιο του μεταπτυχιακού προγράμματος ‘Αναλυτική Χημεία & Νανοτεχνολογία’ και απευθύνεται σε ευρύ ακροατήριο.
Σύνδεσμος:
https://upatras-gr.zoom.us/j/96020984114?pwd=ZTJuaFRtdTRGOW9aaC9FbmJralZTUT09
Meeting ID: 960 2098 4114
Passcode: 254846
Σύντομο βιογραφικό του ομιλητή.
Dr. Andrea Carfi holds a Master of Science in Physics from University of Canterbury in UK, Laura degree (equivalent to Master of Science in Chemistry) from Pavia University, Italy, and a PhD in Biophysics from the Université Joseph Fourier in Grenoble, France. He was also trained as a postdoctoral fellow in the laboratories of Prof. Stephen Harrison and Prof. Don Wiley at Boston Children’s Hospital/Harvard. Dr. Carfi has more than 18 years of experience in drug discovery and vaccine development at Moderna, GSK, Novartis Vaccines and IRBM/Merck. Over the years he has covered roles of increasing responsibility with a focus on structural biology, antigen design, small molecule antivirals discovery and vaccines development. In particular, during the seven years at GSK and Novartis Vaccines, he led the US based Protein Biochemistry team and was responsible for the design, selection, characterization and early development of novel vaccines against infectious disease targets, including HIV, CMV and RSV. Some of these vaccine candidates are now in early and late stage clinical trials. He was also heading the Novartis Vaccines Antigen Design platform across the research sites of Cambridge, US and Siena, Italy. Dr. Carfi joined Moderna in 2017 as Sr. Director of Antigen Design and Selection and Project Leader for the CMV vaccine program now in a Phase 1 clinical trial. Dr. Carfi has become the Head of Research for Infectious Disease since January 2019 and he is currently leading Research for all Moderna Infectious Disease targets.